/
DNTH
$109.60-$2.81 (-2.50%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.3B
56M shares
52-week range
$19.84 – $114.55
95% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$98.60
Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
www.dianthustx.com- Employees
- 92
- IPO / List date
- Sep 12, 2023
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds DNTH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 32,100 | $1.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DNTH yet.
